Corcept Therapeutics Incorporated
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Corcept Therapeutics Incorporated (Nasdaq: CORT) is a commercial-stage biopharmaceutical company that discovers, develops and commercializes drugs modulating cortisol activity at the glucocorticoid receptor to treat severe metabolic, oncologic, psychiatric and endocrine disorders. The company markets Korlym (mifepristone), the first FDA-approved treatment for hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome who have type 2 diabetes or glucose intolerance and have failed surgery or are not candidates for surgery; Korlym is available through a limited network of specialty pharmacies with patient support programs including financial assistance. Corcept advances a pipeline of proprietary selective cortisol modulators, including relacorilant in Phase 3 for Cushing's syndrome (PDUFA target date December 30, 2025) and in Phase 3 ROSELLA trial combined with nab-paclitaxel for platinum-resistant ovarian cancer (PDUFA target date July 11, 2026), where it demonstrated improved progression-free and overall survival in October 2025 ASCO late-breaker data; nenocorilant in Phase 1b with nivolumab for solid tumors; and other candidates targeting antipsychotic-induced weight gain, NASH, triple-negative breast cancer, castration-resistant prostate cancer, endometrial cancer, cervical cancer and platinum-sensitive ovarian cancer post-PARP inhibitor progression. Founded in 1998 and headquartered in Redwood City, California, the company conducts operations primarily in the United States and pursues global regulatory submissions including in Europe. Recent developments include Q3 2025 revenue of $207.6 million versus $182.5 million in Q3 2024, lifted full-year 2025 revenue guidance, initiation of new BELLA trial arms for relacorilant plus nab-paclitaxel with bevacizumab in platinum-sensitive ovarian cancer and in endometrial cancer, a Phase 2 collaboration with Arcagy Research for relacorilant plus nab-paclitaxel in cervical cancer, an ongoing transition to a new specialty pharmacy for Korlym fulfillment, and expansion of over 30 studies across endocrinology, oncology, metabolism and neurology.
Company News
Bank of America Corp DE Grows Holdings in Corcept Therapeutics Incorporated $CORT
Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?
Bank of New York Mellon Corp Invests $49.19 Million in Corcept Therapeutics Incorporated $CORT
BlackRock Inc. Makes New $1.08 Billion Investment in Corcept Therapeutics Incorporated $CORT
Like The Knick's, Corcept Rebounded And Is Crushing It
Mega Cap Growth vs Small Cap Growth: Which ETF Wins?
Trump is up 230% on this stock trade since March
Handelsbanken Fonder AB Boosts Stock Holdings in Corcept Therapeutics Incorporated $CORT
Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term
Raised Guidance Lifts Corcept to 52-Week High
FAS Wealth Partners Inc. Grows Stock Position in Corcept Therapeutics Incorporated $CORT
Avidity Partners Management LP Has $1.21 Million Position in Corcept Therapeutics Incorporated $CORT
Corcept Therapeutics: LIFYORLI Is Likely A Blockbuster, But The Valuation Already Knows It
CORT Q2 Earnings & Revenues Beat Estimates, 2026 Outlook Raised
Corcept Therapeutics Incorporated (CORT) Q2 2026 Earnings Call Transcript
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates
Corcept Therapeutics Q2 Earnings Call Highlights
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
Are Medical Stocks Lagging Corcept Therapeutics (CORT) This Year?
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call